+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Long-term outcome of chemotherapy for advanced testicular and extragonadal germ cell tumors: a single-center 27-year experience

Long-term outcome of chemotherapy for advanced testicular and extragonadal germ cell tumors: a single-center 27-year experience

Japanese Journal of Clinical Oncology 40(1): 73-78

We retrospectively assessed long-term outcomes of chemotherapy for advanced germ cell tumors (GCTs) at our institution. Ninety-five consecutive males with advanced GCTs of the testis or extragonadal origin who received chemotherapy between 1980 and 2006 were enrolled. All patients underwent induction chemotherapy including cisplatin. The median follow-up period was 36.1 months (0 - 288.5) for all patients and 52.6 months (2.2 - 288.5) for the 73 current survivors. Totally, 75 patients (78.9%) achieved complete remission (CR). CR was achieved in 61.1%, 37.9% and 75.0% of the patients after induction therapy, second-line therapy and third-line or more, respectively. As salvage therapy, high-dose chemotherapy was performed in 11 patients (11.7%) and regimens with novel anticancer agents such as paclitaxel and irinotecan were employed for 8 patients (8.5%) from 2003 and later. The era of the treatment, extrapulmonary metastasis and serum alpha-fetoprotein were independent prognostic factors for patients. The 5-year overall survival of patients after 1992 was 83.0%, which was significantly higher than that of those before 1992 (56.3%). CR was never achieved in 20 patients and most of them met the criteria of the poor-prognosis group. Disease recurrence after CR was found in nine patients who were initially classified into the good- or intermediate-prognosis group. Improvement of medical management during chemotherapy and the development of several regimens for salvage chemotherapy seemed to contribute to improving outcomes of patients with advanced testicular cancer. Newly established chemotherapy regimens are needed for improvement of survival of patients in the poor-prognosis group.

(PDF emailed within 0-6 h: $19.90)

Accession: 054168089

Download citation: RISBibTeXText

PMID: 19773268

DOI: 10.1093/jjco/hyp121

Related references

Management and outcome of bilateral testicular germ cell tumors: a 25-year single center experience. International Journal of Urology 15(9): 821-826, 2008

Testicular microlithiasis, chemotherapy for stage I seminoma, and chemotherapy for advanced extragonadal germ cell tumors. Reviews in Urology 4(4): 200-202, 2006

Late recurrence and second primary malignancy among 139 patients with germ cell tumors: long-term outcome of the disease in a single-center experience. Japanese Journal of Clinical Oncology 40(2): 157-162, 2010

Retroperitoneal lymph node dissection in clinical stage I non-seminomatous germ cell testicular tumours Long term results in a single-center 16-year experience. European Urology Supplements 1(1): 94, January, 2002

Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors: A 25-year Single-center Experience. Clinical Genitourinary Cancer 15(6): E1015-E1019, 2017

Extragonadal germ cell tumors eggct 12 year md anderson cancer center experience. Proceedings of the American Association for Cancer Research Annual Meeting 30: 260, 1989

Treatment outcome of patients with extragonadal nonseminomatous germ cell tumors: the Saitama Cancer Center experience. International Journal of Clinical Oncology 18(4): 731-734, 2014

Bilateral testicular germ-cell tumors--a single centre long-term experience. International Urology and Nephrology 33(3): 521-524, 2002

Bilateral testicular germ-cell tumors: A single centre long-term experience. International Urology & Nephrology 33(3): 521-524, 2001

Cisplatin-based chemotherapy of primary extragonadal germ cell tumors. A single institution experience. Cancer 77(3): 526-532, 1996

Clinical Features and Treatment Outcomes in Patients with Extragonadal Germ Cell Tumors: A Single-center Experience. Anticancer Research 36(1): 313-317, 2016

The results of chemotherapy for extragonadal germ-cell tumors in the cisplatin era: the Memorial Sloan-Kettering Cancer Center experience (1975 to 1982). Journal of Clinical Oncology 3(8): 1073-1078, 1985

Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. Journal of Clinical Oncology 13(5): 1188-1194, 1995

Extragonadal germ cell tumors An international analysis of prognostic factors and long term outcome. Onkologie 23(Sonderheft 7): 113, October, 2000

Prognostic factors of long-term outcome in surgically resectable pancreatic neuroendocrine tumors: A 12-year experience from a single center. Oncology Letters 13(3): 1157-1164, 2017